• Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
Inhalation
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
  • Bolagsanalys
  • Pressmeddelanden
  • Prenumerera
  • IPO 2017
  • Finansiering 2025
  • Finansiella rapporter
  • Kalender
  • Ägarlista
  • Bolagstämma
  • Bolagsstyrning
  • Presentationer

Presentationer

Video interview with CEO Manoush Masarrat and CCO Ulf Wedenberg commenting on the Q2, 2025 report and corporate activities ahead

Stockholm Corporate Finance Life Science Seminarium, Capital Markets Day, 2023

Q&A with ISAB CEO Manoush Masarrat (in Swedish)

Stockholm Corporate Finance Life Science Seminarium, Capital Markets Day, 2023

CEO Manoush Masarrat presents Inhalation Sciences AB (in English).

At the link below you can watch the Presentation and explore the full slide deck:

https://ir.financialhearings.com/stockholm-corporate-finance-cmd-2023-9-mars-inhalation-sciences

https://ir.financialhearings.com/stockholm-corporate-finance-cmd-2023-9-mars-inhalation-sciences

Redeye Life Science Day 2021, CEO Manoush Masarrat presents  

Inhalation Sciences mäter partiklar i vår inandningsluft.

Inhalation Sciences – Market potential

 

Contact

Hälsovägen 7
Novum Floor 6, Elevator E
141 57 Huddinge, Sweden.
contact@inhalation.se
+46 (0) 705 625 195

Visitor entrance: Blickagången 6, Floor 6, Elevator E

Useful links
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
      • White paper
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering 2025
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
About Us

Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

Privacy policy

Copyright © 2025 Inhalation. All rights reserved.

Design mkmedia
Contact us!
To top